Publication :
Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth

Notice brève
ali.license-refhttps://creativecommons.org/licenses/by-nc-nd/4.0
ali.license-ref.start-date2021-11-18
bul.description.provenancenoadg -- spbar
dc.contributor.authorBilodeau, Jean-François
dc.contributor.authorGevariya, Nikunj
dc.contributor.authorLarose, Jessica
dc.contributor.authorRobitaille, Karine
dc.contributor.authorFradet, Vincent
dc.contributor.authorRoy, Jérôme
dc.contributor.authorOger, Camille
dc.contributor.authorGalano, Jean-Marie
dc.contributor.authorBergeron, Alain
dc.contributor.authorDurand, Thierry
dc.contributor.authorJulien, Pierre
dc.contributor.authorFradet, Yves
dc.date.accessioned2023-05-24T14:15:57Z
dc.date.available2023-05-24T14:15:57Z
dc.date.issued2020-11-18
dc.description.abstractIntroduction: Cancer has been associated with increased oxidative stress and deregulation of bioactive oxylipins derived from long-chain polyunsaturated fatty acids (LC-PUFA) like arachidonic acid (AA). There is a debate whether ω-3 LC-PUFA could promote or prevent prostate tumor growth through immune modulation and reduction of oxidative stress. Our aim was to study the association between enzymatically or non-enzymatically produced oxidized-LC-PUFA metabolites and tumor growth in an immune-competent eugonadal and castrated C57BL/6 male mice injected with TRAMP-C2 prostate tumor cells, fed with ω-3 or ω-6 LC-PUFA-rich diets. Materials and methods: Tumor fatty acids were profiled by gas chromatography and 26 metabolites derived from either AA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were assessed by liquid chromatography-mass spectrometry. Results: The enriched ω-3 diet did not reduce oxidative stress overall in tumors but favored the formation of ω-3 rather than ω-6 derived isoprostanoids. We discovered that EPA and its oxidized-derivatives like F3-isoprostanes and prostaglandin (PG)F3Aω, were inversely correlated with tumor volume (spearman correlations and T-test, p<0.05). In contrast, F2-isoprostanes, adrenic acid, docosapentaenoic acid (DPAω-6) and PGE2 were positively correlated with tumor volume. Interestingly, F4-neuroprostanes, PGD2, PGF2ω, and thromboxane were specifically increased in TRAMP-C2 tumors of castrated mice compared to those of eugonadal mice. Discussion: Decreasing tumor growth under ω-3 diet could be attributed in part to increased levels of EPA and its oxidized-derivatives, a reduced level of pro-angiogenic PGE2 and increased levels of F4-neuroprostanes and resolvins content in tumors, suspected of having anti-proliferative and anti-inflammatory effects.en
dc.identifier.doi10.1016/j.plefa.2020.102215
dc.identifier.issn0952-3278
dc.identifier.pubmed33276284
dc.identifier.urihttp://hdl.handle.net/20.500.11794/118463
dc.languageeng
dc.publisherScience Direct
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subjectEugonadal miceen
dc.subjectCastrated miceen
dc.subjectInflammationen
dc.subjectOxidative stressen
dc.subjectIsoprostanoidsen
dc.subjectOxylipinsen
dc.subjectAnti-prostate cancer effects of omega-3en
dc.subject.rvmAcides gras oméga 3
dc.subject.rvmProstate -- Cancer
dc.subject.rvmStress oxydatif
dc.subject.rvmMétabolites
dc.titleLong chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth
dc.typearticle de recherche
dcterms.bibliographicCitationProstaglandins Leukot Essent Fatty Acids, Vol. 164, 102215 (2021)
dcterms.dateAccepted2020-11-11
dspace.accessstatus.time2023-05-24 18:07:34
dspace.entity.typePublication
relation.isAuthorOfPublication18c223cb-88ab-4a39-85c8-c1e2e4d31a77
relation.isAuthorOfPublication6489da56-1fa9-45b4-9aaa-8a877a0ac569
relation.isAuthorOfPublication14c26d68-5217-4e50-a729-a66788397b8f
relation.isAuthorOfPublicationdd26bc6f-dd6c-448f-b6f3-721ffe5a69e9
relation.isAuthorOfPublicationdd26bc6f-dd6c-448f-b6f3-721ffe5a69e9
relation.isAuthorOfPublication1dd0b24d-288f-487b-b933-f10c7b2be5a5
relation.isAuthorOfPublication8b507c18-b116-4d51-8168-68f51988c273
relation.isAuthorOfPublication8a1a02df-2ed5-410a-b69b-ee06f8551267
relation.isAuthorOfPublication.latestForDiscovery18c223cb-88ab-4a39-85c8-c1e2e4d31a77
relation.isResourceTypeOfPublication4c433ef5-3937-4530-8252-cca17d715747
relation.isResourceTypeOfPublication.latestForDiscovery4c433ef5-3937-4530-8252-cca17d715747
rioxxterms.project.funder-nameCanadian Urology Oncology Group
rioxxterms.project.funder-nameFonds de recherche du Québec - Santé (FRQS)
rioxxterms.project.funder-nameProstate Cancer Canada
rioxxterms.versionAccepted Manuscript (AM)
rioxxterms.version-of-recordhttps://doi.org/10.1016/j.plefa.2020.102215
Fichiers
Bundle original
Voici les éléments 1 - 1 sur 1
Vignette d'image
Nom :
AM_Bilodeau_et_al.PLEFA-D-20-00034-clean.pdf
Taille :
1.44 MB
Format :
Adobe Portable Document Format
Description :
Télécharger
Bundle de license
Voici les éléments 1 - 1 sur 1
Vignette d'image
Nom :
license.txt
Taille :
922 B
Format :
Item-specific license agreed upon to submission
Description :
Télécharger
Collections
Articles publiés dans des revues avec comité de lecture